Back to top
more

SCYNEXIS, Inc. (SCYX)

(Delayed Data from NSDQ)

$1.04 USD

1.04
134,818

+0.03 (2.97%)

Updated Oct 11, 2019 03:58 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.50%
17.69%
9.28%
4.86%
1.63%
10.50%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | B Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for SCYX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

INDUSTRY: Medical - Drugs

Reports for Purchase

Showing records 61 - 80 ( 16450 total )

Company: Catalyst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 61

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for CPRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 62

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BCRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Jazz Pharmaceuticals PLC

Industry: Medical - Drugs

Record: 63

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for JAZZ

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Opiant Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 64

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for OPNT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Neptune Technologies & Bioresources Inc

Industry: Medical - Drugs

Record: 65

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NEPT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Ironwood Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 66

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IRWD

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eisai Co.

Industry: Medical - Drugs

Record: 67

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ESALY

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 68

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ACRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Nektar Therapeutics

Industry: Medical - Drugs

Record: 69

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NKTR

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: IntelGenx Technologies Corp.

Industry: Medical - Drugs

Record: 70

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IGXT

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ImmunoGen, Inc.

Industry: Medical - Drugs

Record: 71

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for IMGN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Infinity Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 72

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for INFI

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Endo International plc

Industry: Medical - Drugs

Record: 73

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ENDP

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Bio-Path Holdings, Inc.

Industry: Medical - Drugs

Record: 74

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BPTH

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Neurocrine Biosciences, Inc.

Industry: Medical - Drugs

Record: 75

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NBIX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: NovaBay Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 76

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for NBY

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: DURECT Corporation

Industry: Medical - Drugs

Record: 77

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for DRRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: BioSpecifics Technologies Corp

Industry: Medical - Drugs

Record: 78

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for BSTC

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Rigel Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 79

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for RIGL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: ArQule, Inc.

Industry: Medical - Drugs

Record: 80

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ARQL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party